Drugs / CTX310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07491172 | Jun 2024 → Jun 2027 expected | cardiovascular disorder, homozygous familial hypercholesterolemia, hypertriglyceridemia, lip disorder | CRISPR Therapeutics AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-08-28 | CRISPR Therapeutics | Results CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 crisprtx.com ↗ |
| 2025-11-08 | CRISPR Therapeutics | Results CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering crisprtx.com ↗
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced positive Phase 1 data from its ongoing clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. |
| 2025-06-26 | CRISPR Therapeutics | Results CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline crisprtx.com ↗
The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. |
| 2025-05-06 | CRISPR Therapeutics | Results CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 crisprtx.com ↗ |
| 2023-11-06 | CRISPR Therapeutics | Results CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 crisprtx.com ↗
CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491172 ↗ |
| Modality | CRISPR / gene editing | “clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components” NCT07491172 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT07491172 ↗ |
| Target | ANGPTL3 | “target gene angiopoietin-like 3 (ANGPTL3)” NCT07491172 ↗ |